Deals Of The Week: Sandoz/Fougera, Abbott/Action Pharma/Zealand, AstraZeneca/Axerion
New company Tolero helps MannKind de-risk a preclinical BTK inhibitor program in a “double-jointed” deal in which the “bio-bucks” eventually could flow in either direction.
You may also be interested in...
Escrow service Shareholder Representative Services, which oversees a good portion of earnout-based deals, has published exclusive data that show, among other things, that one-third of post-acquisition milestones are paying out.
AstraZeneca’s neuroscience innovative medicines unit (iMED) begins to take shape through a pair of deals with Link Medicine Corp. and with four academic labs.
For a single $110 million payment, the soon-to-be-split Abbott gets global rights to AP214, a Phase IIb compound designed to prevent acute kidney damage caused by hypoxia during cardiac surgery.